Sedation and Analgesia Usage in Severe Pandemic H1N1 (2009) Infection: A Comparison to Respiratory Failure Secondary to Other Infectious Pneumonias

Abstract

Spanish

French

BACKGROUND:

During the 2009 H1N1 pandemic (pH1N1), patients requiring mechanical ventilation for respiratory failure received high doses of sedation and analgesia.

OBJECTIVE:

To examine sedation and analgesia use among patients with respiratory failure due to severe pH1N1 infection compared to other infectious pneumonias.

METHODS:

In this observational cohort study of intensive care unit (ICU) patients with respiratory failure, we compared doses of sedatives and analgesics administered to patients with pH1N1, non-pH1N1 viral pneumonia, and adult respiratory distress syndrome (ARDS) secondary to bacterial pneumonia, on days 1, 3, 7, 14, and 28 of ICU admission. Cumulative drug use, daily drug use, and weight-adjusted medication doses were examined.

RESULTS:

The study population consisted of 37 patients with pH1N1 infection, 22 patients with non-pH1N1 viral pneumonia, and 46 patients with ARDS secondary to bacterial pneumonia. To achieve similar levels of sedation using the Richmond Agitation Sedation Scale, patients with pH1N1 were administered the highest cumulative median doses of fentanyl (11, 230 μg; interquartile range [IQR] 3240-21, 000), compared to 2400 μg (IQR 130-7130) in viral pneumonia and 2880 μg (IQR 600-6950) in ARDS (p < 0.001). Patients with pH1N1 were also administered the highest cumulative median doses of midazolam at 820 mg (IQR 330-1160), compared to 160 mg (IQR 20-390) in viral pneumonia and 160 mg (IQR 20-480 mg) in ARDS (p < 0.001). The pH1N1 group received the highest median daily fentanyl and midazolam doses on all study days. The pH1N1 group did not differ significantly in cumulative propofol dose compared with the other 2 study groups.

CONCLUSIONS:

Sedative and analgesic use may be uniquely higher in critically ill patients with pH1N1 infection compared to patients with other infectious pneumonias. This finding may be important for resource planning in future pandemics. Further study is required to explore the underlying mechanisms for potentially higher sedative and analgesic requirements in this patient population.

Keywords

intensive care mechanical ventilation pH1N1 respiratory failure sedation

Get full access to this article

View all access options for this article.

References

Harrigan

Webb

Seppelt

The practical experience of managing the H1N1 2009 influenza pandemic in Australian and New Zealand intensive care units. Crit Care Resusc 2010;12:121–30.

Arroliga

Frutos-Vivar

Hall

Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest 2005;128:496–503.

3 Brush

Kress

. Sedation and analgesia for the mechanically ventilated patient. Clin Chest Med 2009;30:131–41,ix.

Arroliga

Thompson

Ancukiewicz

Use of sedatives, opioids, and neuromuscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome. Crit Care Med 2008;36:1083–8.

Kahn

Andersson

Karir

Low tidal volume ventilation does not increase sedation use in patients with acute lung injury. Crit Care Med 2005;33:766–71.

Wolthuis

Veelo

Choi

Mechanical ventilation with lower tidal volumes does not influence the prescription of opioids or sedatives. Crit Care 2007;11:R77. DOI 10.1186/cc5969.

7 Fan

Khatri

Mendez-Tellez

Shanholtz

Needham

. Review of a large clinical series: sedation and analgesia usage with airway pressure release and assist-control ventilation for acute lung injury. J intensive Care Med 2008;23:376–83.

8 Van Rompaey

Elseviers

Schuurmans

Shortridge-Baggett

Trujen

Bossaert

. Risk factors for delirium in intensive care patients; a prospective cohort study. Crit Care 2009;13:R77. DOI 10.1186/cc7892.

9 Pisani

Murphy

Araujo

Slattum

Van Ness

Inouye

. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med 2009;37:177–83.

10.

Brook

Ahrens

Schaiff

Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999;27:2609–15.

11.

11 Kress

Pohlman

O'Connor

Hall

. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000;342:1471–7.

12.

Girard

Kress

Fuchs

Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008;371:126–34.

13.

Treggiari

Ramand

Yanez

Randomized trial of light versus deep sedation on mental health after critical illness. Crit Care Med 2009;37:2527–34.

14.

14 Weber

Kane

Oriolo

Saul

Skledar

Dasta

. Impact of intensive care unit (ICU) drug use on hospital costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. Crit Care Med 2003;31:S17–24.

15.

15 Dasta

Kane-Gill

. Pharmacoeconomics of sedation in the ICU. Crit Care Clin 2009;25:571–83.

16.

Ely

Truman

Shintani

Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 2003;289:2983–91.

17.

17 D'Angio

Platt

Gannon

. Creatinine clearance: corrected versus uncorrected. Drug Intell Clin Pharm 1988;22:32–3.

18.

18 Khosla

Steiner

. The MDRD equation predicts peritoneal dialysis–delivered creatinine clearances from serum creatinine. Clin J Am Soc Nephrol 2009;4:798–803.

19.

19 McAuley

. Opioid (narcotic) analgesic converter. www.globalrph.com/narcotic.cgi (accessed 25 Aug 2011).

20.

Funk

Siddiqui

Wiebe

Practical lessons from the first outbreaks: clinical presentation, obstacles, and management strategies for severe pandemic (pH1N1) 2009 influenza pneumonitis. Crit Care Med 2010;38:e30–7.

21.

21 Gin

Kumar

Zarynchanski

Honcharick

. H1N1 patients in the ICU (letter). CMAJ 2009;181:500.

22.

22 Casati

Putzu

. Anesthesia in the obese patient: pharmacokinetic considerations. J Clin Anesth 2005;17:134–45.

23.

23 Baily

Ward

Musa

. Clinical pharmacokinetics of benzodiazipines. J Clin Parmacol 1994;34:804–11.

24.

24 Cotreau

von Moltke

Greenblatt

. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33–60.

25.

25 Greenblatt

Harmatz

von Moltke

Wright

Shader

. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 2004;76:467–79.

26.

Miao

Jin

Marunde

Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics 2009;9:319–26.

27.

Kumar

Zarychanski

Pinto

Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009;302:1872–9.

28.

Zarychanski

Stuart

Kumar

Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010;182:257–64.

29.

29 La Ruche

Tarantola

Barboza

Vaillant

Gueguen

Gastellu-Etchegorry

. The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific. Euro Surveill 2009;14: ppii =19366.

30.

30Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives–-12 states, 2009. MMWR Morb Mortal Wkly Rep 2009;58:1341–4.

31.

31 Spriet

Merrsseman

de Hoon

von Winckelmann

Wilmer

Willems

. Clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med 2009;35:603–12.

32.

32 McKindley

Boucher

Hess

Rodman

Feler

Fabian

. Effect of acute phase response on phenytoin metabolism in neurotrauma patients. J Clin Pharmacol 1997;37:129–39.

33.

Perez-Padilla

de la Rosa-Zamboni

Ponce de Leon

Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009;13:680–9.

34.

34 Bental

. Acute psychoses due to encephalitis following Asian influenza. Lancet 1958;2:18–20.

35.

Morishima

Togashi

Yokota

Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 2002;35:512–7.

36.

Kawada

Kimura

Ito

Systemic cytokine responses in patients with influenza-associated encephalopathy. J Infect Dis 2003;188:690–8.

37.

Toovey

Rayner

Prinssen

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Safety 2008;31:1097–114.

38.

38 Davies

. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010;65:ii5-10.